Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Does the assessment of diastolic Function play any role in this scenario?
Answer from Dr Helfen:
The 2016 ESC position paper on cancer treatments (EHJ (2016) 37,2768-2801) lists “heart failure with preserved ejection fraction”, another term for “diastolic dysfunction with normal ejection fraction” as a baseline risk factor for cardiotoxicity. Therefore, these patients need a careful follow-up. In the case of manifestation of cardiotoxicity with a decrease of more than 10% percentage points below the lower limit of normal diastolic dysfunction is always present. In this situation we start the therapy recommended for patients with heart failure due to cardiomyopathy. Therefore, assessment of diastolic function plays a role.
Doctor Harald H BecherMazankowski Alberta Heart InstituteAlberta, Canada
Doctor Andreas Helfen St Marien Hospital Medizinische Klinik ILÜnen, Germany
Professor Piotr LipiecDepartment of CardiologyMedical University of Lodz, Poland
The webinar addresses cardiologists working in the field of multimodality imaging (Echo, CMR, Nuclear) and cardiovascular imaging community.
During the webinar, you will be encouraged to send your questions by chat and interact with our key opinion leaders who will provide live feedback.
The webinar is available on PC and Tablets. The use of a smartphone is not recommended.
To answer the MCQs during the live, you must allow pop-up windows.
A high-speed Internet connection is required (minimum 2 Mbps).
This programme is supported by Philips in the form of an educational grant.
The scientific programme has not been influenced in any way by its sponsor.
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 Biot
06903, Sophia Antipolis, FR
This programme is supported by BRACCO in the form of an educational grant.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved